Key Insights

Highlights

Treatment Research

3 treatments under study, led by Adjuvant Immunotherapy

Research Leaders

6 sponsors active, led by First Affiliated Hospital, Sun Yat-Sen University

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05877872Phase 3Recruiting

Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma

Showing all 1 trials

Research Network

Common Treatments

  • Adjuvant Immunotherapy1
  • Reducedtarget Resection1
  • Fulltarget Resection1

Active Sponsors

  • First Affiliated Hospital, Sun Yat-Sen University1
  • Nanfang Hospital, Southern Medical University1
  • Sun Yat-sen University1
  • Fifth Affiliated Hospital of Guangzhou Medical University1
  • First People's Hospital of Foshan1

Top Investigators

Related Conditions

  • Nasopharyngeal Carcinoma1

Activity Timeline